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Abstract Trastuzumab-based therapy has been shown to
confer overall survival benefit in HER2-positive patients
with advanced gastric cancer in a large multicentric trial
(ToGA study). Subgroup analysis identified adenocarcino-
mas of the stomach and gastroesophageal (GE) junction
with overexpression of HER2 according to immunohisto-
chemistry (IHC) as potential responders. Due to recent
approval of trastuzumab for HER2 positive metastatic
gastric and GE-junction cancer in Europe (EMEA) HER2
diagnostics is now mandatory with IHC being the primary
test followed by fluorescence in situ hybridization (FISH)
in IHC2+ cases. However, in order to not miss patients
potentially responding to targeted therapy determination of
a HER2-positive status for gastric cancer required modifi-
cation of scoring as had been proposed in a pre-ToGA
study. To validate this new HER2 status testing procedure
in terms of inter-laboratory and inter-observer consensus for
IHC scoring a series of 547 gastric cancer tissue samples on
a tissue microarray (TMA) was used. In the first step, 30
representative cores were used to identify specific IHC
HER2 scoring issues among eight French and German
laboratories, while in the second step the full set of 547
cores was used to determine IHC HER2 intensity and area
score concordance between six German pathologists.
Specific issues relating to discordance were identified and
recommendations formulated which proved to be effective
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Introduction
The human epidermal growth receptor 2 gene (HER2, also
known as ERBB2 and HER2/neu) is now well recognized as
a key in the development of certain solid human tumors,
most notably in breast cancer. In breast cancer, HER2 gene
amplification almost invariably induces and occurs before
HER2 protein overexpression on the tumor cell surface [1,
2]. Monitoring of the tumor HER2 status (gene amplifica-
tion and/or protein overexpression) in breast cancer has
become routine as the positive HER2 status detected in
around 25% of these cancers is associated with poorer
prognosis, more aggressive disease, and an increased risk of
disease recurrence [3–5]. Furthermore, in breast cancer the
determination of HER2 status is necessary for optimal
application of HER2-directed therapies such as trastuzumab
(Herceptin®, Roche), which increases overall survival in
both the metastatic [6, 7] and adjuvant settings [8–10], and
predicts response in the neo-adjuvant setting [9, 10].
Data reported in the literature for HER2 positivity rates
in gastric cancer vary from about 7–43% (for review see,
[11]) with most studies demonstrating values of about 15–
25% [11–14]. Furthermore, a HER2-positive status in
gastric cancer also appears to be associated with poorer
prognosis, more aggressive disease, and shorter survival
[12, 14–19]. Preclinical studies have indicated that trastu-
zumab exerts antitumor activity in HER2-overexpressing
human gastric cell lines and xenograft models [19–21]. As
a consequence, the addition of trastuzumab to fluoropyr-
imidine/platinum-based therapy has been investigated in a
large-scale (n=584) randomized study in patients with
HER2-positive advanced gastric cancer, the ToGA trial,
the primary results of which have been presented and
showed that trastuzumab significantly improved the prima-
ry endpoint, median overall survival, by nearly 3 months
(11.1 to 13.8 months, p=0.0046) with no impact on overall
treatment safety. Moreover, an increased benefit from
trastuzumab treatment was seen for patients who had higher
levels of HER2 protein expression, including subgroups for
IHC2+/FISH+ and IHC3+ (median survival increased from
11.8 months for the chemotherapy treatment arm to
16.0 months for the chemotherapy with trastuzumab arm)
[22, 23]. Thus, very recently the European board, EMEA,
approved trastuzumab for the treatment of metastasized
adenocarcinomas of the stomach and the esophageal
junction [24]. Thereby immunohistochemical testing is the
primary method of choice to determine HER2 status in
gastric cancer. FISH is restricted to those cases that have
equivocal (IHC2+) HER2 expression.
The method of HER2 scoring within the phase III ToGA
trial was essentially based on a separate (so-called pre-ToGA)
validation study where immunohistochemistry (IHC) protein
expression and fluorescence in situ hybridization (FISH) gene
amplification was correlated in a series of 168 gastric cancer
resection specimens [11]. An international consensus was
reached to modify the breast scoring system for IHC by
accepting strong incomplete (basolateral) membranous stain-
ing as positive (3+) and by abolishing the 10% area cut-off for
this group in biopsies. A patient was considered to have
HER2-positive gastric cancer with a score of IHC3+
(HercepTest) and/or FISH-positive result. Screening of nearly
4,000 patients in 24 countries for entry to the ToGA trial
revealed a 22.1% HER2-positivity rate [25]. Furthermore,
HER2-positivity rates were higher in gastroesophageal junc-
tion than gastric cancer (33% vs. 21%, p<0.001) and in
intestinal than diffuse or mixed cancer (32.2% vs. 6.1% vs.
20.4%, p<0.001). Concordance between IHC and FISH was
87.5%: while in breast cancer, most IHC0/1+ results are FISH
negative, the frequency of IHC0/1+ samples testing as FISH-
positive was similar as IHC2+/FISH-positive samples (23%
vs. 26%) [25].
The aim of our current study was to validate this HER2
testing procedure by determining whether pathologists from
different sites are able to reproduce the method of gastric
cancer HER2 status evaluation as it was used by the study
pathologist (JR) within the ToGA study.
In a first step, inter-laboratory variation was assessed
using 30 gastric cancer core biopsy tissue microassay
samples (TMAs) using different HER2 IHC methods. In a
second step, inter-observer variation of HER2 IHC scoring
was tested in a series of already stained gastric cancer
TMAs (n=547). A consensus practical guideline for
accurate HER2 analysis in gastric cancer was then
developed on the basis of these data. Finally, for validation
of these guidelines a series of 447 prospective diagnostic
gastric cancer specimens were tested at five participating
sites throughout Germany.
Materials and methods
All study TMAs were based on a series of 547 gastric cancer
core biopsy specimens assembled and provided by Prof.
Kreipe (Hannover). All individual patients gave written
informed consent for biological studies at their initial
presentation. All samples were obtained from surgery
performed for diagnostic and/or therapeutic purposes and
were used according to German ethical regulations. The study
followed the guidelines of the Declaration of Helsinki and
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anonymous in the context of this study.
In a first step, a 30-core TMA set was pre-selected that
provided a representative of all tumor types (intestinal,
mixed, and diffuse) according to Lauren classification as
well as different HER2 expression and amplification levels.
Core size was 0.4 cm and each represented a different
tumor sample. HER2 assessment was performed using
different commercial assays according to the manufac-
turers’ instructions at the different participating sites (n=8).
IHC immunostaining was conducted using HercepTest™
(Dako Denmark A/S, Glostrup, Denmark) and/or the
PATHWAY® HER2/neu (4B5) antibody (Ventana Medical
Systems SA, Illkirch, France). HER2 amplification was
determined by FISH assays, using either HER2 FISH
pharmDX™ (Dako Denmark A/S) or PathVysion® (Abbott
Laboratories, Des Plaines, IL, USA). Automated bright-
field dual-color silver in situ hybridization (SISH) assay
(BDISH; Inform™, Ventana Medical Systems SA) was
used to determine gene amplification at three of the
participating sites [26]. Evaluation was performed accord-
ing to the modified gastric cancer testing protocol [11]
taking incomplete basolateral or only lateral staining into
account. As TMA cores were tested analogous to biopsies
the 10% cut-off was recorded but not regarded for the final
scoring (i.e., 1+, 2+, and 3+). FISH and BDISH were
performed according to the manufacturers’ recommenda-
tions with ratios above 2.0 being considered amplified.
In a second step, the complete TMA sample series of
547 tumor cores was used to determine inter-observer
variation of HER2 expression (staining intensity and area
stained) scoring independent of inter-laboratory staining
variation. Thus, TMAs used for evaluation were already
IHC stained using the 4B5 antibody (Ventana Medical
Systems SA) at the Hannover laboratory that supplied
samples.
Data for the first 30-core TMA set were presented and
discussed at a 2-day consensus meeting conducted at the
Institute of Pathology, Charite, Berlin (27/28 March 2009).
After a consensus was reached about specific issues concerning
HER2 scoring by IHC in gastric cancer, the second full set of
547 cores were evaluated independently by six German
pathologists (GB, MD, HH, JR, SA, AW). The complete 547
TMA set was scanned (Provito GmbH, Berlin, Germany) and
providedasvirtualslidestothepanelists.Byuseofthisdataset,
all cases that resulted in discordant IHC scores between
observers were then individually discussed at a separate
meeting in Düsseldorf (10 June 2009) to determine the most
reproducible practical guideline for HER2 testing in gastric
cancer. Statistical analyses were performed using the statistical
program R version 1.9.1 and Microsoft® Excel®. Kappa
statistics was calculated according to the method of Conger
(1980) by package “irr” of program R [33]. In order validate
these guidelines in routine practice a series of n=447
prospective diagnostic gastric cancer samples have been tested
at five different participating sites throughout Germany which
comprised either a biopsy tissue block or one representative
tissue block of resection specimen. Thereby, four sites
followed the algorithm as proposed by EMEA with IHC
(4B5, Ventana) being used first and one center applied both
IHC and ISH (BDISH, Ventana) to all n=152 specimens at
their site.
Results
Inter-laboratory reproducibility of HER2 scoring in gastric
cancer
In total, 29 of 30 cores of the first TMA set showed evaluable
tumor tissuewhenevaluatedbyHercepTestand4B5antibody
at 7 and 8 sites, respectively. The core with non-evaluable
tumor tissue was excluded. A HER2 score deviation ≤1w a s
found in 14/29 cores (48.3%) when HercepTest was used as
compared to 22/29 cores (75.9%, p=0.002) when 4B5 was
used, despite one more site being included for the latter.
Consensus HER2 scores was reached for all but 1 site for 11
(37.9%) tumors with HercepTest and by 13 (44.8%) tumors
with 4B5. Consensus HER2 scores between sites with each
IHC test increased as a function of fewer sites being in
agreement.
In total, 27 tumor cores were evaluable for HER2 gene
amplification by hybridization assays. Comparison with
HER2 amplification according to FISH/BDISH results with
HER2 IHC scores unanimously agreed by all sites as
negative (0/1+) or positive (2+/3+) revealed a tendency
towards higher sensitivity for 4B5 detecting positive HER2
amplification (Table 1). In particular, five out of eight ISH-
positive tumor cores were scored as 2+/3+ by 4B5 whereas
this was the case in only two cores with HercepTest; IHC
scoring was equivocal with some positive and some negative
classifications in three cases by 4B5 and six cases by
HercepTest, respectively. There was no difference between
both test platforms with respect to the ISH-negative cases
with the one equivocal case testing negative at some sites
and as positive at others.
Pitfalls and rules of HER2 IHC scoring
Reviewing of the 30 core TMA slides disclosed several
pitfalls that were mainly related to interpretation of staining
rather than staining variation at different lab sites. After
panel discussion the following pitfalls turned out to be the
major reasons for inter-oberserver variation. Figure 1 shows
examples of potential pitfalls and of different scores that
can be obtained by HER2 receptor staining. HER2
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sia and towards reactive epithelial cells bordering ulcers
(Fig. 1a). Discordant results can also occur where <10% of
tumor cells are stained. This holds particularly true if only a
few (<5) cells were evaluated. Such small cell groups tend
to show unspecific rather pericellular and granular instead
of distinct intercellular staining particularly at the edges of
the TMA cores (Fig. 1b). Another source of false positive
scoring is diffuse cytoplasmic reaction with or without
nuclear staining (Fig. 1c). For evaluation of membranous
staining specific for scoring it turned out that consideration
of microscope magnification is of importance to reach high
inter-observer agreement. Accordingly, strong HER2-
positive (3+) staining may be visible to the naked eye and
displays unequivocal membranous staining already at low
magnification (×2.5/×5) as shown in Fig. 2d,e. An example
of heterogeneous staining is given in Fig. 1f. Areas of 3+
HER2-positive cells (visible at low magnification ×2.5) in
less than 10% of tumor cells are admixed with those where
unequivocal membraneous staining can only be disclosed at
medium magnification (first at ×10 corresponding to 2+
intensity) and with some areas showing barely visible
expression (membranous staining confirmed only at ×40,
corresponding to 1+). Fig. 1g shows focal staining (<10%
of the tumor) where unequivocal membranous staining
could first be recognized at medium magnification (×10,
Fig. 1h). In contrast demonstration of IHC 1+ score needs
high magnification (×40) to confirm an unequivocally
intercellular membranous HER2 expression (Fig 1i).
Figure 2 summarizes the recommended stepwise process
of standardized IHC scoring in gastric cancer. At first tumor
and tissue quality issues have critically to be checked. Most
of all, unspecific staining within non-neoplastic lesions
such as intestinal metaplasia have to be excluded from
scoring and also edge and crushing artifacts affecting tumor
cells. In a second step, only distinct membranous staining
either complete (chicken-wire type), basolateral or only
lateral between cell–cell contacts in a cluster of at least five
cells are considered if biopsies are scored. This excludes
any equivocal staining, e.g., rather thickened or granular at
basal cell basement membrane or at a single isolated cell
surrounded by a shrinkage rim. Any staining at the luminal
site of a tumor gland is suspicious of artifactual staining not
specific for scoring particularly if it is not associated with
distinct intercellular staining and should therefore be
excluded. In the third step the final scoring should be done
taking the microscope magnification into account at which
unequivocal membrane staining can readily be confirmed.
Inter-observer reproducibility of HER2 scoring in gastric
cancer
After discussion and definition of the above-mentioned
pitfalls and rules for reliable IHC scoring the full TMA set
(547 cores) stained by 4B5 was graded with respect to both
intensity and area scores by six pathologists. A HER2 score
deviation ≤1 between pathologists was now found for 95.6%
and 91.8% of TMAs for intensity and area scores, respective-
ly. Consensus agreement for HER2 staining intensity scores
between all except 1 or 2 of the 6 pathologists was found for
512/547 (93.6%) and 470/547 (85.9%) tumors, respectively,
while corresponding consensus agreement for area stained
scores rates were 505/547 (92.3%) and 465/547 (85.0%)
tumors, respectively.
Calculation of interrater kappa values showed moderate
agreement (k=0.61) if all intensity scores (IHC 0–3+) were
considered. However, if negative (IHC 0/1+) was calculated
against positive (IHC2+/3+) kappa value rose to 0.805
indicating an “almost perfect agreement”. In fact, this
implies that 92.5% of the six pathologists were in complete
agreement in all 547 cores. In five cases, there was marked
discordance with half scoring a case IHC 0/1+ and half
IHC2+/3+. Reevaluation of these cases (Düsseldorf meet-
ing) disclosed that in all of these cases the number of
evaluable tumor cells was below five cells.
Validation of guidelines by application to diagnostic
specimens
In order to demonstrate the value of the defined IHC
scoring rules with respect to routine practice and gene
amplification status a total of 447 diagnostic gastric cancer
Table 1 Inter-laboratory comparison: comparison of HER2 amplification status according to FISH/BDISH results with HER2 IHC scores
FISH/BDISH result
(n=27)
IHC score
4B5 HercepTest
Negative
(0/1+)
Equivocal
(0/1+ vs. 2+/3+
Postive
(2+/3+)
Negative
(0/1+)
Equivocal
(0/1+ vs. 2+/3+
Positive
(2+/3+)
Negative (n=18) 12 5 1 11 7 0
Equivocal (n=1) 0 1 0 0 1 0
Positive (n=8) 0 3 5 0 6 2
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sites (Berlin, Dresden, Hannover, Kassel, Munich). The
mean positivity rate was 22.8% (102/447). In one site, both
IHC and ISH test were applied in parallel to a total of 152
gastric carcinomas. Accordingly, the consented testing
guidelines resulted in a high concordance between IHC
and ISH. All IHC3+ tumors (n=24) showed HER2 gene
amplification (100% concordance), which was the case in
32% of the IHC2+ (n=47) and in 5% of the IHC 1+ (n=41)
cases. Interestingly, most of IHC2+ and IHC1+ (76.5%)
showed low level amplification (ratio 2–3) which was only
the case in 16% of IHC3+ tumors.
Fig. 1 Photomicrographs of TMA examples. a–c Artifacts leading to
potential mis-scoring on IHC: a intestinal metaplasia, b edge artifact at
TMA border with granular (not linear) pseudo-membranous staining,
and c cytoplasmic as well as nuclear staining. d–h Intensity scoring: d
Score 3+ visible by naked eye with membranous staining clearly
visible at low magnification (obj. ×5) being either complete, baso-
lateral or lateral (e, ×10). f Photomicrograph of TMA sample showing
distinction between 2+ and 3+ IHC using 4B5 antibody. Arrows
indicate areas with clearly visible membrane staining at low
magnification (i.e., 3+), focally in <10% of tumor); arrowheads
indicate areas where membrane staining is only visible at ×10
magnification (i.e., 2+). g TMA core suspicious of some focal staining
at ×5 which turned out to be a focally specific membranous staining in
groups of at least five cells at medium magnification (h, ×20; see
arrowheads). i Very weak staining where membranous staining is
barely visible and could only be demonstrated using high magnifica-
tion (i, ×40)
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The modified HER2 immunoscoring method that has been
shown to be predictive of response to trastuzumab-based
therapy in patients with advanced gastric cancer in the ToGA
study [22] was shown to be reproducible between different
pathologists in our study as long as special precautions were
adopted. Furthermore, our study indicates that HER2 status
determination in gastric cancer needs special and specific
training and guidelines for pathologists in a similar manner to
that already adopted for pathologists for breast cancer testing.
However, the specific guidelines for breast cancer are not
applicable to gastric cancer in several aspects, as there are
important and significant differences in HER2 status determi-
nation between breast and gastric cancer (Table 2).
Thus determination of HER2 status by just transferring
the breast cancer IHC scoring roles to gastric cancer may
lead to a significant loss of patients. In a recent paper by
Barros-Silva et al. [27], resection specimens of 463 gastric
adenocarcinomas were tested using the breast cancer
scoring rules. Accordingly, these authors classified 3.9%
as IHC2+ and 5.4% as IHC3+. The corresponding values in
the TOGA trial with 12% IHC2+ and 11% IHC3+ were
about twice as high [23]. The same holds true if one
compares TMA data which were classified as IHC2+
(1.6%) or IHC3+ (3.2%) if breast cancer scoring was
applied [28]. As the same group also tested gastric cancer
TMAs using our proposed gastric cancer specific scoring
[11] the corresponding rates were 4% IHC2+ and 13% for
IHC3+, demonstrating an about fourfold increase of HER2
positivity rate [29]. Therefore, it is supposed that applica-
tion of breast cancer scoring to gastric cancer may produce
an up to 50% false-negative rate if IHC is used as the
primary test platform as favored by EMEA.
On the other hand, if FISH is used as first screening step
only few IHC3+ positive cases may be missed but one may
be faced with a quite high percentage of non-responders
according to ToGA data [22, 23].
Therefore, based on the presented consensus study a
number of specific recommendations can be made for reliable
Fig. 2 Stepwise approach to IHC scoring in gastric cancer: tissue and quality issues (mod. acc. to [31])
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expression is mainly restricted to intestinal-type, gland-
forming gastric cancer cells incomplete, often basolateral or
only lateral, membranous IHC staining is the rule rather than
an exception for HER2-positive gastric cancer [11]. Thus,
unlike for breast cancer, circularity of IHC staining is no
longer a criterion for HER2 IHC scoring in gastric cancer.
A key issue for the classification of positive HER2
expression is a membranous staining that can be unequivocally
assessed as linear staining at cell–cell contact sites. Strong
tumor HER2 IHC staining is usually already directly visible,
particularly if most of the tumor is stained. In these cases, only
low magnification (×2.5–5) is needed to confirm strong
staining intensity. In any case where high magnification (×40)
is required for unequivocal demonstration of membranous
staining, the tumor is scored IHC 1+ (Fig. 1i). It should,
however, be mentioned that quality of lenses and brightness of
the microscopic light might be of influence as well.
Nevertheless the inter-observer variation results within this
ring-study prior and after application of the magnification rule
clearly are in favor of such an approach over non-standardized
wording, e.g., of “barely visible” for IHC1+.
Recommendation 1
For reproducible intensity scoring, the degree of microscopic
magnification (x-fold) at which membranous (linear intercel-
lular) staining is clearly visible should be considered.
According to the pre-ToGA HER2 validation study [11],
IHC HER2 expression is often focal in gastric cancer which
could largely be confirmed by the ToGA study [25]. An
assessment area cut-off of at least 10% stained tumor cells,
as originally proposed for HER2 scoring in breast cancer,
was omitted in gastric cancer biopsies. A rather focal HER2
staining was also frequently observed in our current series
of TMAs. Inter-observer agreement was especially low if
less than five cells were stained. The minimum number of
cells that could reliably be assessed was five. Thus, in
biopsies a focus (“clone”) that is allowed to be scored
should have at least five stained evaluable cells.
Recommendation 2
Since focal HER2 expression is an issue in gastric cancer,
biopsies should only be it evaluated if at least five cohesive,
unequivocal tumor cells are stained. In resection specimens,
the 10% cut-off should be kept. Thus scoring procedure is
different for biopsies and resection specimen [23].
Thereby, only unequivocal intercellular staining is accept-
ed; even ring-shaped staining of a single tumor cell is not
accepted either due to the cell number criterion (see above) or
difficulties in exclusion of edge artifacts. The pre-ToGA
HER2 scoring validation study used HercepTest as the only
IHC assay [11]. The different laboratory sites generally used
two different IHC assays (HercepTest and 4B5) concurrently.
Both assays resulted in a somewhat degree high inter-
laboratory discordance, which appeared to be higher when
HercepTest was used. These observations could essentially
be confirmed by the validation set where 4B5 was used in
447 prospective stomach cancers and in parallel with BDISH
in 152 of these cases. Interestingly, all IHC3+ tumors
showed HER2 gene amplification.
Table 2 HER2 diagnostics in gastric cancer—differencies to breast cancer (acc. to [32])
Gastric cancer Breast cancer
IHC scoring Extent
(Area Cut-off)
Biopsy specimens≥5 Cells
Resection specimens: ≥10%
≥10% (≥30%)
a
Circularity Mostly missing (often only lateral
in IHC2+/3+)
A must in IHC2+/3+
(F)ISH analysis Cell number 20 cohesive tumor cells showing
highest gene count
(add 20 new if ratio 1.8–2.2)
20 cohesive tumor cells showing
highest gene count
(add 20 new if ratio 1.8–2.2)
Amplification Ratio≥2.0 Ratio≥2.0 (≥2.2)
a
HER2 positivity Tumor type About 30% of intestinal-type GC
about 15% of mixed-type
about 5% of diffuse type
(signet ring type typically negative)
15–25% of ductal type (G2/G3);
almost never in subtypes such
as lobular, medullar and ductal
G1
Tumor location About 30% at cardiac/GE-junction
about 15% of gastric cancer
No correlation
Patient selection FISH vs. IHC IHC more predictive than FISH:
IHC primary test
b FISH only if IHC2+
FISH/IHC equally predictive:
aAcc. to ASCO/CAP [31]
bAcc. to approval by EMEA
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Use of FDA approved antibodies is recommended for
selection of HER2-positive patients in gastric cancer.
Besides HercepTest which was applied in the ToGA study
another antibody approved by the FDA for breast cancer
testing (4B5) appeared to be at least as sensitive, possibly
showing even higher inter-laboratory concordance for
HER2 IHC scoring and a closer relationship between
IHC3+ and HER2 gene amplification.
Given the evolving and provisional status of HER2
status determination for gastric cancer, we make a final
recommendation as follows.
Recommendation 4
Participation in proficiency testing tools such as QUIP
(Qualitätssicherungs-Initiative der Deutschen Gesellschaft
für Pathologie und des Berufsverbandes Deutscher Pathol-
ogen zur diagnostischen Immunhistochemie und Molekular-
pathologie) at the Dresden Laboratory is strongly
recommended since HER2 testing is quite different in gastric
cancer as compared to breast cancer (www.ringversuch.de).
Wecouldshowthatapplicationoftheconsentedguidelines
to a total of 447 diagnostic gastric cancer specimens resulted
in a positivity rate of 22.8% which is quite in the range of the
ToGA study with22.1% [25]. Within a subset of 153 tumors,
all cases were tested in parallel by IHC and ISH. A complete
concordance between both methods could be demonstrated
within the IHC3+ group being all amplified by BDISH.
Even so, according to ToGA trial data amplification was not
sufficient enough to reliably detect the patients that had a
significant benefit from trastuzumab therapy [22]. Although
most of amplified IHC0 and IHC1+ cases had low level
amplification (ratio 2–3) both in ToGA and in our own
validation series up to now it is not quite clear whether there
is a predictive correlation between therapy response and
amplification level in gastric cancer which is obviously not
the case in breast cancer [30].
Finally, it turned out that due to heterogeneity of at least
some advanced GC both in the mixed-type and in the
intestinal-type precise scanning of tumors is of importance
particularly if FISH techniques at high magnification
(×100) are used. This might be in favor for light-
microscopically based ISH techniques where even small
amplified tumor cell foci can readily be recognized (data
not shown).
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